A Phase 4 interventional study of Trelegy Ellipta 100/62.5/25Mcg Inh 30D and Brimica in Chronic Obstructive Pulmonary Disease, sponsored by Fundacio Privada Mon Clinic Barcelona. Terminated at 1 site in Spain. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-08-14.
Sponsored by Fundacio Privada Mon Clinic Barcelona · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 309 studies in Pulmonary Disease, Chronic Obstructive with a site in Spain — 42 open to participants now, 45 under way, 9 of them phase 3. Pulmonary Disease, Chronic Obstructive · Spain.
Among the 309 studies in Pulmonary Disease, Chronic Obstructive with a site in Spain, this one is the 204th largest by enrollment of the 238 interventional ones that give a count, is one of 12 that started in 2024, is one of 40 in phase 4, and was the 275th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →42 of the 309 studies in Pulmonary Disease, Chronic Obstructive with a site in Spain are open now. Recruiting first, the newest first:
Grifols Therapeutics LLC · Sites in Spain, United States, Denmark and 6 more countries
Ages 18–80
Aether Tech S.L. · Sites in Spain
Ages 40–90
Pfizer · Sites in Spain, United States, Argentina and 15 more countries
Ages 35–80
Hospital Universitario La Paz · Sites in Spain
Ages 45–75
Clinica Universidad de Navarra, Universidad de Navarra · Sites in Spain
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
309 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 33 · Phase 3 97 · Phase 4 40
First in 2000; this study’s year is marked. 12 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is below the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 336 across the 238 interventional studies, 254 across the 70 observational. Of the 217 that completed or were terminated, 112 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
169 of 309 have an industry lead sponsor. The 10 most frequent:
Fundacio Privada Mon Clinic Barcelona is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
Fundacio Privada Mon Clinic Barcelona has 2 studies filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
12 of the studies in Pulmonary Disease, Chronic Obstructive with a site in Spain that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
| NCT07555483Phase 3Grifols Therapeutics LLCA Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD) | 2027-09-30 |
| NCT07679646Air Liquide Healthcare SpainEffectiveness and Efficiency of Home Telemonitoring and Non-invasive Ventilation in Patients With COPD and Hypercapnia (EVALECO) | 2026-12 |
| NCT07432191Iconic Solutions By Murcia SLMedical Device Clinical Trial Without CE Marking to Evidence Safety and Performance of the INBENTUS VERSATILE Ventilator in Patients Requiring Assisted/Controlled Mechanical Ventilation and Weaning. | 2026-12 |
| NCT07938086Aether Tech S.L.Automated Oxygen Titration With the EMILY.AI Device During the Six-Minute Walk Test | 2026-12-20 |
Add all 12 to your calendar (.ics) → With an account.
Among the 309 studies in Pulmonary Disease, Chronic Obstructive with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Current guidelines recommend initial treatment with dual long-acting bronchodilator therapy (LABA-LAMA) in patients with Chronic Obstructive Pulmonary Disease (COPD) of group B (defined by CAT≥10 and none or 1 moderate exacerbation). However, the investigators hypothesize that there is a subgroup of B patients (B+) at a particularly high risk for poor clinical control, characterized by the following:
the investigators further hypothesize that B+ patients could benefit from triple therapy treatment (LABA-LAMA + Inhaled Corticosteroids). Therefore, the main goal of this clinical trial is to compare the efficacy of Trelegy (triple therapy) in improving clinical control in GOLD B+ patients with chronic obstructive disease when compared to standard double therapy (LABA -LAMA).
The clinical control is a validated composite endpoint that includes two domains, the patient's stability, and the impact of the disease.
1028 patients will be randomly allocated to receive either the standard therapy or Trelegy and will be monitored by the investigators for 1 year in 2 on-site visits + 2 remote visits.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
B+ phenotype
Exclusion Criteria:
Unstable or life-threatening cardiac disease, including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Trelegy commercial product. 1 inhalation daily for 12 months
Drug: Trelegy Ellipta 100/62.5/25Mcg Inh 30D
Any LABA-LAMA combination approved in Spain is accepted. To be used according to product specifications for 12 months.
Drug: Brimica · Drug: Duaklir · Drug: Ultibro · Drug: Ulunar · Drug: Xoterna · Drug: Anoro · Drug: Laventair · Drug: Spiolto Respimat · Drug: Yanimo · Drug: Foradil · Drug: Broncoral · Drug: Formoterol stada · Drug: Oxis · Drug: Formatris · Drug: Formoterol Aldo · Drug: Onbrez · Drug: Oslif · Drug: Hirobriz · Drug: Striverdi · Drug: Beglan · Drug: Betamican · Drug: Inaspir · Drug: Serevent · Drug: Soltel · Drug: Eklira · Drug: Bretaris · Drug: Seebri · Drug: Tovanor · Drug: Enurev · Drug: Spiriva · Drug: Tavulus · Drug: Sirkava · Drug: Braltus · Drug: Gregal · Drug: Incruse · Drug: Rolufta
Product to be used according to specifications. 1 inhalation daily for 12 months
Also known as: LABA/LAMA/ICS
As per product specifications
Also known as: LABA/LAMA
As per product specifications
Also known as: LABA/LAMA
As per product specifications
Also known as: LABA/LAMA
As per product specifications
Also known as: LABA/LAMA
As per product specifications
Also known as: LABA/LAMA
As per product specifications
Also known as: LABA/LAMA
As per product specifications
Also known as: LABA/LAMA
As per product specifications
Also known as: LABA/LAMA
As per product specifications
Also known as: LABA/LAMA
As per product specifications
Also known as: LABA
As per product specifications
Also known as: LABA
As per product specifications
Also known as: LABA
As per product specifications
Also known as: LABA
As per product specifications
Also known as: LABA
As per product specifications
Also known as: LABA
As per product specifications
Also known as: LABA
As per product specifications
Also known as: LABA
As per product specifications
Also known as: LABA
As per product specifications
Also known as: LABA
As per product specifications
Also known as: LABA
As per product specifications
Also known as: LABA
As per product specifications
Also known as: LABA
As per product specifications
Also known as: LABA
As per product specifications
Also known as: LABA
As per product specifications
Also known as: LAMA
As per product specifications
Also known as: LAMA
As per product specifications
Also known as: LAMA
As per product specifications
Also known as: LAMA
As per product specifications
Also known as: LAMA
As per product specifications
Also known as: LAMA
As per product specifications
Also known as: LAMA
As per product specifications
Also known as: LAMA
As per product specifications
Also known as: LAMA
As per product specifications
Also known as: LAMA
As per product specifications
Also known as: LAMA
As per product specifications
Also known as: LAMA
Clinical Control (CC)
Patient persistently controlled by CC at all study visits (a subject to be categorized as having clinical control they must meet the criteria at month 3, 6, 9 and 12).
Time frame: 3,6,9 and 12 months
Clinical Important Deterioration (CID)
Patients persistently non deteriorated by CID-CAT at all study visits.(a subject to be categorized as having control by CID-CAT they must meet the criteria a month 3, 6, 9 and 12).
Time frame: 3,6,9 and 12 months
Patients persistently controlled
Patients persistently controlled (at all visits) throughout the study between the two study arms as per: * CC - Stability Domain 1. General status since the last visit 2. Exacerbations in the last 3 months * CC - Impact Domain 1. Sputum color 2. Rescue medication use 3. Minutes walked per day 4. Dyspnea (mMRC) * CID-CAT - Exacerbations * CID-CAT - (Patient reported outcomes)PROs * CID-CAT - Lung function
Time frame: 3,6,9 and 12 months
Time to deterioration
time to first event of not being CC or suffer CID-CAT
Time frame: 3,6,9 and 12 months
Time to no control event of CC - Stability Domain
Time to first no control event for CC - Stability Domain
Time frame: 3,6,9 and 12 months
Time to no control event of CC - Impact Domain
Time to first no control event for CC - Impact Domain
Time frame: 3,6,9 and 12 months
Time to deterioration event of CID-CAT Exacerbations
Time to deterioration event for CID-CAT Exacerbations
Time frame: 3,6,9 and 12 months
Time to deterioration event of CID-CAT Spirometry
Time to deterioration event for CID-CAT Spirometry
Time frame: 3,6,9 and 12 months
Exacerbation rate
To compare several Health status related endpoints between study arms including: d.To evaluate the mean and annual rate of: * Moderate exacerbations (ECOPD) * Severe ECOPD (hospitalized) * Moderate and Severe ECOPD
Time frame: 3,6,9 and 12 months
Time to first Exacerbation
To compare several Health status related endpoints between study arms including: e.To evaluate time to first ECOPD including: * Moderate ECOPD * Severe ECOPD (hospitalized) * Moderate or Severe ECOPD
Time frame: 3,6,9 and 12 months
Spirometry changes
To compare several Health status related endpoints between study arms including: f. To assess annual FEV1(Forced Expiratory volume) and FVC (forced vital capacity) changes (ml/year)
Time frame: 3,6,9 and 12 months
Independent predictors
Independent predictors with a potential negative impact on achieving the CC, each of its domains and each of its variables at each study visit.
Time frame: 3,6,9 and 12 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2024 to primary completion in Jan 2025, 10 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
Fundacio Privada Mon Clinic Barcelona